Bookmark and Share
BioAssay: AID 602143

Cellular PLD2 isoenzyme activity assays at a set concentration

Phospholipase D (PLD) generates the lipid second messenger phosphatidic acid as part of a plethora of cellular functions. Phosphatidic acid (PtdOH) is a critical signaling lipid that is generated by the hydrolysis of phosphatidylcholine and other amine containing phospholipids. Phosphatidic acid participates in both G protein-coupled receptor and receptor tyrosine kinase signal transduction more ..
_
   
 Tested Compounds
 Tested Compounds
All(418)
 
 
Active(56)
 
 
Inactive(363)
 
 
 Tested Substances
 Tested Substances
All(424)
 
 
Active(56)
 
 
Inactive(368)
 
 
AID: 602143
Data Source: Vanderbilt Specialized Chemistry Center (PLD2_Assay_1B)
BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2011-12-12

Data Table ( Complete ):           View Active Data    View All Data
Targets
Sequence: phospholipase D2 isoform PLD2B [Homo sapiens]
Description ..   
Protein Family: Catalytic domain, repeat 2, of vertebrate phospholipase D2

Gene:PLD2          More BioActivity Data..


more...  
BioActive Compounds: 56
Related Experiments
Show more
AIDNameTypeProbeComment
588854Summary AID for PLD inhibitor development projectSummary3 depositor-specified cross reference: Summary AID for PLD inhibitor development project
624000PLD2 purified enzyme concentration response (PLD2_Assay_3B_Lib32)Confirmatory depositor-specified cross reference
624001PLD1 purified enzyme concentration response (PLD1_Assay_3A_Lib32)Confirmatory depositor-specified cross reference
624003PLD1 Cellular concentration response (PLD1_Assay_2A_Lib32)Confirmatory depositor-specified cross reference
624004PLD2 Cellular concentration response (PLD2_Assay_2B_Lib32)Confirmatory depositor-specified cross reference
624008PLD1 Cellular isoenzyme activity (PLD1_Assay_1A_Lib32)Screening depositor-specified cross reference
624009PLD2 Cellular isoenzyme activity (PLD2_Assay_1B_Lib32)Screening depositor-specified cross reference
602144Cellular PLD1 isoenzyme activity assays at set concentrationScreening same project related to Summary assay
602147Cellular PLD2 concentration responseConfirmatory same project related to Summary assay
602149PLD2 purified enzyme concentration responseConfirmatory same project related to Summary assay
602150PLD1 purified enzyme concentration responseConfirmatory same project related to Summary assay
602151Cellular PLD1 concentration responseConfirmatory same project related to Summary assay
602153ML270, ML271, ML272 Competition in Radioligand Binding assays (Ricerca)Other same project related to Summary assay
602175Developing isoenzyme selective inhibitors of phospholipase D as an antiviral therapeutic - Secondary Assay PanelOther same project related to Summary assay
623933ML298, ML299 Competition in Radioligand Binding assays (Ricerca)Other same project related to Summary assay
Description:
Phospholipase D (PLD) generates the lipid second messenger phosphatidic acid as part of a plethora of cellular functions. Phosphatidic acid (PtdOH) is a critical signaling lipid that is generated by the hydrolysis of phosphatidylcholine and other amine containing phospholipids. Phosphatidic acid participates in both G protein-coupled receptor and receptor tyrosine kinase signal transduction networks. Two mammalian isoforms of PLD have been identified, PLD1 and PLD2, which share 53% sequence identity and are subject to different regulatory mechanisms (1). Inhibition of PLD enzymatic activity leads to increased cancer cell apoptosis, decreased cancer cell invasion, and decreased metastasis of cancer cells (2,3); therefore, the development of isoform-specific PLD inhibitors is a novel approach for the treatment of cancer.

In addition to the importance of PLD in cancer cell survival it has been shown that this enzyme is the major source of signaling PtdOH in many cells, including neutrophils, macrophages, and airway epithelial cells that play key roles in defense against infection. PLD1 was recently confirmed as a primary regulator of Fc-gamma receptor-stimulated ROS production in neutrophils (4) using a strategic combination of genetic knockouts and pharmacological inhibitors. A recent report in Nature identified PLD2 as a gene that when downregulated drastically reduced viral replication of a panel of influenza strains including avian H5N1, endemic H1N1 and the pandemic swine flu of 2009 (5), although two related reports (6,7) using similar approaches failed to identify PLD isoenzymes as being relevant in influenza. Also because of PLD's role in vesicular trafficking, more specifically the link between PLD activity and influenza virus haemagglutinin (HA) trafficking to the plasma membrane (8), we hypothesize that this enzyme is a critical target to combat influenza infection. Current therapeutics strategies rely on vaccines or molecules targeting viral neuraminidase, both of which are subject to rapid resistance development.

In preliminary findings, PLD1 and PLD2 have been strongly implicated as playing essential roles in the entry of influenza virus into human airway epithelial cells. Given that PLD1-and PLD2-knockout animals are viable and appear to lack any obvious deficits, we hypothesize that PLD is a novel and therapeutically attractive target for blocking influenza infection. We propose to optimize potency, isoenzyme selectivity, and drug metabolism/pharmacokinetic parameters to develop chemical tool compounds into a preclinical lead compound for therapeutic development.

The development of these tool compounds will be essential in understanding the roles played by PLD in modulating cell responses to oxidative stress that is involved in a variety of human diseases including cancer, infectious disease, cardiovascular diseases and other conditions that are consequences of chronic, pathological inflammation. The development of these tool compounds has empowered the PLD signaling field. Still, major challenges remain to develop more potent and selective compounds that differentiate between PLD1 and PLD2 isoenzymes.

As previously described (2) this is accomplished through a set of parallel assays:

The primary screen will be a parallel single dose screen in two different cell lines. To determine if compounds are active against cellular PLD1, phorbol 12-myristate 13-acetate (PMA) stimulated Calu-1 cells will be used. It has previously been shown that under these conditions the PLD activity in these cells is strictly due to the PLD1 isozyme. A parallel PLD2 centric assay is also carried out using HEK293 cells stably overexpressing gfp-PLD2. Data is expressed as percent activity which is calculated from the vehicle control samples present in each assay with background lipid signals subtracted.

After initial hits are identified using the above parallel primary screens compounds with >50% inhibition for both isoforms, or compounds which display isoform preferential inhibition are further characterized using cellular concentration response curves in each of the previously described cell types. A concentration response curve is generated using GraphPad Prism 4 software and IC50 values are obtained from the non-linear curve fitting (sigmoidal dose reponse) of the data.

1. Selvy, P.E., et al., Phospholipase D: enzymology, functionality, and chemical modulation. Chem Rev, 2011. 111(10): p. 6064-119.
2. Scott, S.A., et al., Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol, 2009. 5(2): p. 108-17.
3. Lavieri, R.R., et al., Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor. J Med Chem, 2010. 53(18): p. 6706-19.
4. Norton, L., et al., PLD1, rather than PLD2, regulates phorbol ester-, adhesion dependent-, and Fcgamma receptor stimulated reactive oxygen species production in neutrophils. Journal of cell science, 2011. 124(12): p. 1973-83.
5. Karlas, A., et al., Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature, 2010. 463(7282): p. 818-22.
6. Shapira, S.D., et al., A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. Cell, 2009. 139(7): p. 1255-67.
7. Brass, A.L., et al., The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell, 2009. 139(7): p. 1243-54.
8. Bi, K., M.G. Roth, and N.T. Ktistakis, Phosphatidic acid formation by phospholipase D is required for transport from the endoplasmic reticulum to the Golgi complex. Curr. Biol., 1997. 7(5): p. 301-7.
9. Brown, H.A., et al., Biochemical analysis of phospholipase D. Methods Enzymol., 2007. 434: p. 49-87.
Protocol
PLD2 cellular screens in single point concentration.
HEK293-gfpPLD2a cells are plated at 250,000 cell/well into poly-lysine coated 12-well tissue culture plates in DMEM 10% FBS 1% AA (antibiotic-antimycotic). After 48 hours media is then removed and cells are pretreated with DMEM containing either compound (at 200 nM) or vehicle control for 5 minutes at room temperature. After pretreatment media is changed out and cells are treated with DMEM containing screening compound (200 nM, and 0.3% n-butylalcohol-d10 for 30 min at 37 degrees C.
After incubation, treatment media is removed, plates are placed on ice and to each well 600 uL 0.1N HCl:methanol (1:1) is added. Cells are then dislodged using a cell scraper and transferred to bullet tubes on ice. The cellular lipids are extracted via a modified Bligh-Dyer extraction by addition of 300 uL ice cold chloroform and internal standard (50 ng 32:0 PtdMeOH/sample in chloroform). Samples are then mixed and centrifuged for 5 min at 4 degrees C. The lower layer (organic phase) is then isolated. The organic phase is then evaporated in a CentriVap and resulting lipid film is redisolved in 80 uL 90% Methanol 10% chloroform plus 1 uL NH4OH.
Resulting solution is then directly infused into a Thermofinnigan TSQ Quantum triple quadrupole MS and detected using negative ionization mode. Data is collected over a 1 minute infusion of solution. The PLD2 lipid products, 34:1 phosphatidylbutanol-d9 (m/z 738) and 32:1 phosphatidylbutanol-d9 (m/z 710) is quantitated using standard curves and internal standards. Data is expressed as percent activity which is calculated from the vehicle control samples (=100% activity) present in each assay with background lipid signals subtracted (using no butanol treated samples). Assay is performed once in triplicate. Average values are reported with 'Active' threshold at 50.0% activity or less.
Comment
All libraries with the exception of Library 30 were run at 200nM single point concentration point. Library 30 was screened with a 20uM concentration point.
Categorized Comment - additional comments and annotations
From PubChem:
Assay Cell Type: HEK293
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1HEK293_PLD2_MeanAveraged Percent PLD1 Activity at set concentrationFloat%
2HEK293_PLD2[1]Measured Percent PLD1 Activity at set concentrationFloat%
3HEK293_PLD2[2]Measured Percent PLD1 Activity at set concentrationFloat%
4HEK293_PLD2[3]Measured Percent PLD1 Activity at set concentrationFloat%
5HEK293_PLD2[4]Measured Percent PLD1 Activity at set concentrationFloat%
6HEK293_PLD2[5]Measured Percent PLD1 Activity at set concentrationFloat%
7HEK293_PLD2[6]Measured Percent PLD1 Activity at set concentrationFloat%
Additional Information
Grant Number: P01 ES013125

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
PageFrom: